KAKEN PHARMACEUTICAL

Japan

Country: Japan

Ownership: -

Established: 1948-01-01

Employees: -

Market Cap: -

Website: http://www.kaken.co.jp/

Clinical Trials

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Volunteers - Male and Female

Interventions: Drug: KP-001
Drug: Moxifloxacin 400 mg
Drug: Placebo

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-28

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT06649942

Locations: 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

Phase 1

Not yet recruiting

Conditions: Healthy Adults
Hepatic Impairment

Interventions: Drug: KP-001

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT06619054

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy Adults

Interventions: Drug: KP-001
Drug: Clarithromycin
Drug: Metformin
Drug: Midazolam

First Posted Date: 2024-01-29

Last Posted Date: 2024-03-27

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 38

Registration Number: NCT06227832

Locations: 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

Phase 3

Completed

Conditions: Periodontitis

Interventions: Drug: Trafermin

First Posted Date: 2009-11-18

Last Posted Date: 2013-10-21

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 25

Registration Number: NCT01015404

Locations: 🇯🇵
Kaken Investigational Site 2, Matsudo, Japan
🇯🇵
Kaken Investigational Site 1, Sapporo, Japan
🇯🇵
Kaken Investigational Site 4, Shinjuku-ku, Japan

and more 3 locations

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: KP-413 Ointment

First Posted Date: 2009-07-02

Last Posted Date: 2012-04-06

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 58

Registration Number: NCT00932074

Locations: 🇺🇸
Oregon Medical Research Center, PC, Portland, Oregon, United States
🇺🇸
Michigan Center for Research Corp, Clinton Twp., Michigan, United States
🇺🇸
J & S Studies, Inc., College Station, Texas, United States

and more 3 locations

Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)

Phase 3

Completed

Conditions: Periodontitis
Alveolar Bone Loss
Periodontal Attachment Loss

Interventions: Drug: Placebo
Drug: Trafermin (genetical recombination)

First Posted Date: 2008-08-14

Last Posted Date: 2012-06-15

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 328

Registration Number: NCT00734708

Locations: 🇯🇵
Kaken Investigational Site, Tokushima, Japan

Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2

Phase 2

Completed

Conditions: Periodontitis

Interventions: Drug: Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)

First Posted Date: 2007-08-10

Last Posted Date: 2007-08-10

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 91

Registration Number: NCT00514657

A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan

Phase 2

Completed

Conditions: Periodontitis

Interventions: Drug: Trafermin (genetical recombination)

First Posted Date: 2005-09-20

Last Posted Date: 2008-02-05

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 267

Registration Number: NCT00199290

Locations: 🇯🇵
Kaken Investigational Site, Tokushima, Japan

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy